OCS Stock Forecast & Price Target

Oculis Holding is favorably positioned because its pipeline shows multiple shots on goal across high-value ophthalmology and neuro-ophthalmology, led by privosegtor and licaminlimab, with de-risking signals from Phase 2 efficacy, structure preservation, and biomarker data. The ACUITY findings showing lower NfL and GFAP versus placebo, plus the 18-letter LCVA benefit at Month 3, strengthen the neuroprotective rationale for PIONEER, while the PREDICT-1 program in DED has encouraging genotype-enriched Phase 2 results, including a −4.3-point symptom advantage and 17.9% versus 4.7% achieving >20-point improvement. Financially, the bull case is supported by an estimated $2.38B market value, $282.3M cash, and modeled peak annual sales of $1.7B for licaminlimab, though execution and regulatory risk remain important.

Oculis Holding is facing a materially weaker fundamental profile after the Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed to meet the primary BCVA endpoint in both studies, prompting management to abandon an FDA filing for that indication. Although retinal thickness improved and the drug was well tolerated, the failure of the key efficacy measures undermines confidence in the program’s commercial potential and removes a major value driver from the model, leaving the company more dependent on earlier-stage assets. With an estimated market value of $1.56B, $277.6M cash, and only 45% probabilities of approval for OCS-02 and OCS-05, the stock faces elevated clinical, regulatory, commercialization, and dilution risk.